HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODS Botanical Online Fact Sheets Expected By Year-End

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health Office of Dietary Supplements, in conjunction with the National Center for Complementary & Alternative Medicine, plans to make consumer fact sheets about botanicals available online by the end of 2000. ODS and the Warren Grant Magnuson Clinical Center also are collaborating on 12 previously announced vitamin/mineral fact sheets.

You may also be interested in...



ODS Releases Fact Sheets On Vitamins A, D, E

Use of vitamin D supplements for cancer prevention is inadvisable without substantiating data, the National Institutes of Health recommends to consumers in a new "fact sheet" on the fat-soluble vitamin.

NIH Office To "Improve Scientific Methodology" Of Supplement Research

One goal of the National Institutes of Health Office of Dietary Supplements over the next three to five years is to "improve scientific methodology as related to the study of dietary supplements," according to the ODS strategic plan, released Sept. 21.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel